⌕
Krystal Biotech · KRYS · Nasdaq
Tenet 66 · Solid
Compare
$298.55+0.22%At closeTenet 66 · Solid
$298.55+0.65 (+0.22%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Krystal Biotech (KRYS) Earnings Forecast

Analysts expect Krystal Biotech (KRYS) to earn $7.67 a share in FY26, the average of 8 estimates as of Nov 16, 2026.

Sources Analyst estimates EstimatesConsensus as of How we compute thisNot investment advice

3 figures withheld by our checks. Each blank figure names its reason.

FY26 consensus EPS
$7.67
8 analysts
FY27 consensus EPS
$9.27
9 analysts · low $7.45, high $10.57
EPS revisions, 31 days
+3.0%
$7.45 to $7.67
Disagreement, FY26
8.9%
high to low, $7.40 to $8.08

Consensus estimates only. Analysts' price forecasts and ratings are not licensed here.

Consensus as of Nov 16, 2026 · we check it nightly

Analysts expect Krystal Biotech to earn $31.40 a share in FY30, growing about 42% a year; 4 analysts publish an estimate for FY30.

Forward P/E · FY26E
38.8×
$297.90 (as of close, Nov 16, 2026) ÷ $7.67 consensus EPS
Coverage · FY26
8 · 6
EPS estimates · revenue estimates

Are estimates going up or down lately?

The FY26 EPS consensus is $7.67, up 2.9% in 90 days. Every figure compares one fiscal period at both ends.

EPS consensus, change over the last 90 days. One step per nightly change.

−3.3%+1.2%+5.8%FY26 +2.9%FY27 +2.4%Aug 18Nov 16
EPS30 days90 daysshown aboveSince Jul 6
FY268 analysts▲ +3.0%$7.45 to $7.67▲ +2.9%$7.46 to $7.67◆ 0.0%$7.67 to $7.67
FY279 analysts▲ +0.3%$9.24 to $9.27▲ +2.4%$9.05 to $9.27▼ −4.4%$9.69 to $9.27
Dec '266 analysts▲ +5.1%$1.94 to $2.04▲ +4.8%$1.95 to $2.04▲ +4.8%$1.95 to $2.04
Mar '272 analysts24 of 30 days+1.2% so far24 of 90 days+1.2% so far▲ +1.2%$2.07 to $2.09

Contributors at both ends of the window: FY26 8 and 8. A change in the average can come from a new contributor as much as from a changed mind, so both counts stay in view.

Measured between two of our own nightly snapshots of one fiscal period, so a new fiscal year entering the view is never read as a revision. Never backfilled. A window still filling says how many days it holds; a blank one means our record is not that long yet.

If the Street is right, what does that imply for the share price?

Price as of close, Nov 16, 2026 · consensus as of Nov 16, 2026

At 40.8 times earnings, which is what Krystal Biotech trades at today, the FY27 consensus of $9.27 works out to $378 a share.

Consensus EPS · FY27
$9.27
9 analysts · low $7.45, high $10.57 · thin coverage
Multiple · today's trailing P/E
40.8×
$297.90 (as of close, Nov 16, 2026) ÷ $7.30, the last four reported quarters, including EPS computed by Tenet
×
Receipt · KRYS · FY27Nov 16, 2026
Implied, a share
$378

Range on the low and high estimate: $304 to $431.

$304 low$431 high
9.27 × 40.8, to the dollar
Drag the multipleShaded: where Krystal Biotech's P/E sat at each fiscal year end, FY24 to FY25. Each dot is one year.
32×35×40×45×50×55×58×
today 40.8×5-yr avg 44.2×10-yr median 44.2×$378 a share

Each point on the line is a multiple, and the flag is the price it implies for FY27. Past multiples are context, not a guide to future ones.

This is multiplication, not a forecast. It assumes the market pays the multiple you chose and that the consensus is right. Both are often wrong.

You are paying 38.8 times the FY26 consensus for earnings the Street expects to grow about 24% a year to FY28. That is 1.7 times the growth rate.Show today's multiple against its own recordHide the multiple record
Trailing P/E at each fiscal year end, FY24 to FY25 · over 2 fiscal years, with 1 year of near-zero earnings left out. The mark is the median of the last 2.
40.8× today
36.0× low52.3× high
44.2× median
Forward 38.8× is a different measure, so it is not placed on a trailing record. Today's mark is the trailing 40.8×, on the same basis as every year behind it.

How much do analysts disagree?

For FY30, estimates run from $28.85 to $34.87 around an average of $31.40, drawn by 4 analysts.

FY26E8 analysts
$7.40 to $8.08 · 8.9%
FY27E9 analysts
$7.45 to $10.57 · 33.7%
FY28E7 analysts
$6.91 to $14.28 · 62.9%
FY29E2 analysts
$20.77 to $25.10 · 19.1%
FY30E4 analysts
$28.85 to $34.87 · 19.1%

The dashed line is FY25 filed $6.84, on the GAAP basis.

A wide spread is disagreement, not risk; a narrow one is agreement, not accuracy. Later years are always wider because fewer people forecast them. Bars in amber rest on fewer than 15 analysts. The tick on each bar is the average.

Is next quarter a high bar or an easy one?

Analysts expect Krystal Biotech to earn $2.04 a share in the December quarter, the average of 6 estimates. Results are expected by Feb 16, 2027. Last quarter, which ended in September, Krystal Biotech earned $2.05 a share. Analysts had expected $1.79, so it came in 14.6% higher.

$1.69
$2.04high $2.32
low $1.91
+20.9%crosses bases
Dec 2025 quarterfiled · GAAPDec 2026 quarterconsensus · Street basis · 6 analysts
Expected report
Feb 16, 2027
Expected by Feb 16. An estimate, not a date the company has set. Companies move it.
Revenue expected · December quarter
$134.0M
5 analysts, 131.8 to 136.2 in $M · 107.1 in the same quarter a year ago

The step from a filed quarter to a consensus crosses bases: the filed figure is the company's own GAAP number and the consensus is on the Street's basis. It is printed with both bases named, not as growth. For the March quarter, analysts expect $2.09 a share.

Does Krystal Biotech usually beat or miss?

So far we have checked 10 quarters, of which 7 came in above the estimate we held. We add a quarter to this record each time Krystal Biotech reports. The next report is expected by Feb 16, 2027.

We started recording estimates on Jul 6, 2026, so quarters that reported before that date cannot be checked.

Our record, one quarter per report
Dec '23left out
−88.7%
Mar '24reaction
−2.6%
Jun '24left out · adjusted
−8.4%
Sep '24reaction
−3.1%
+29.2%
Dec '24reaction
not held
−15.9%
Mar '25reaction
−14.1%
+8.9%
Jun '25reaction
−14.0%
+144.1%
Sep '25reaction
+0.2%
+10.1%
Dec '25reaction
+4.1%
+22.8%
Mar '26reaction
filing date only
+3.7%
Jun '26reaction
−8.4%
+14.6%
Sep '26reaction
−11.0%
reportsFeb 16
Dec '26
Checked so far
10 quarters
one more every report
Beat expectations
7 of 10
full details on the Earnings tab
Share price reaction
−0.9%
the average over the 8 of 10 checked quarters we could time to a release
Typical gap vs estimate
+9.5%
shown once 4 quarters are checked

Checked against the company's reported figure (GAAP) and the average estimate we recorded the night before its results release. Where analysts' number is on an adjusted basis, we leave the comparison out rather than force it. We started recording estimates for Krystal Biotech on Jul 6, 2026, so earlier quarters cannot be checked, and we never fill them in after the fact. Mar '24, Sep '24, Dec '24, Mar '25, Jun '25, Sep '25, Dec '25, Mar '26 are drawn hollow: we hold no estimate for those quarters recorded strictly before the report, so it is scored against the last estimate we hold rather than the night-before one.

The Street expects sales to grow 29.9% in FY27 and EPS 20.8%. Sales do all of it and the other two take some back: the net margin moves from 46.6% to 46.6%, and the implied share count from about 30.2M to 32.5M, so these numbers assume no buyback.Show the decomposition and the margin ladderHide the decomposition
FY27 EPS growth, in points
Revenue growth+29.9
Net margin change0.0
Share count change−9.1
EPS growth+20.8
Legs are rounded to a tenth of a point and the largest remainder carries the difference, so they add to the total. Implied shares = consensus net income ÷ consensus EPS, a direction rather than a decimal.
8 analysts publish an EPS estimate for FY26 and 6 publish revenue. Coverage thins with distance: 4 EPS estimates for FY30. Consensus figures are on the Street's basis and filed figures are GAAP; we label the gap, we do not explain it away.Show coverage by year and over timeHide the coverage chart
Analysts by fiscal year · outlined revenue, filled EPS. Amber marks a panel of fewer than 15.
68
FY26E
79
FY27E
87
FY28E
62
FY29E
64
FY30E
The FY26 panel has held 8 analysts every night since our record of it began on Jul 6, 2026.

The full consensus, year by year

Consensus as of Nov 16, 2026 · filed figures as reported
Revenue · $Bfiled · consensus average · band = low to high
−0.11.02.2historyStreet forecastFY23FY25FY30E

Coverage thins with distance: 6 revenue estimates for FY26, 6 for FY30.

Diluted EPS · $filed · consensus average · band = low to high
−7.9114.2836.48historyStreet forecastFY22FY25FY30E

Out-year bands widen as fewer analysts publish: 8 EPS estimates for FY26, 4 for FY30.

Fiscal yearRevenue $BYoYEPS $YoYEBITDA $BNet inc. $BShares BAnalysts rev · EPSFwd P/E
FY25Filed0.4—6.84————as filed40.8×
FY26E0.50.5 to 0.5▲27.9%a7.677.40 to 8.08▲12.2%a0.30.20.036 · 838.8×
FY27E0.60.6 to 0.7▲29.9%9.277.45 to 10.57▲20.8%0.40.30.037 · 932.2×
FY28E0.80.7 to 1.1▲30.6%11.716.91 to 14.28▲26.4%0.50.40.038 · 725.4×
FY29E1.41.3 to 1.5▲68.5%22.6120.77 to 25.10n/cb0.90.70.036 · 213.2×
FY30E1.91.8 to 2.1▲35.4%31.4028.85 to 34.87n/cb1.20.90.036 · 49.5×

Average estimate with low to high beneath. Amber counts mark thin coverage and thin rows carry an amber rule. Shares = consensus net income ÷ consensus EPS, a direction rather than a decimal. The filed row's last column is today's price over the last four reported quarters, the one trailing multiple in that column. a This step crosses the seam: last year is a filed GAAP actual and this year is a consensus estimate, so the two are not prepared on one basis. b More than a third of the analyst panel changed between these two years, so the difference of the two averages measures the panel rather than the forecast.

These are consensus estimates: what analysts expect the business to earn, not where they think the stock trades. Coverage thins and the low to high band widens in the out-years. Context, not advice.

Analysts' price forecasts and grades are not licensed here. This page shows forward consensus estimates only: 8 EPS estimates for FY26, 6 for revenue. Not investment advice.

What do analysts expect Krystal Biotech to earn in FY26?

Analysts expect Krystal Biotech to earn $7.67 a share in FY26, the average of 8 estimates as of Nov 16, 2026.

What is Krystal Biotech's earnings forecast for FY27?

The FY27 consensus for Krystal Biotech is $9.27 a share from 9 analysts, with a low of $7.45 and a high of $10.57, as of Nov 16, 2026.

Have analysts raised Krystal Biotech's earnings estimates?

Krystal Biotech's FY26 EPS consensus rose 2.9% in 90 days, from $7.46 to $7.67, as of Nov 16, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.